SCHEMBL4853028

SCHEMBL4853028

CSc1ccc(-c2nc(SC)c(C#N)c(=O)n2-c2ccc(C(C)C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.50
ALDH1A1 P00352 5/20 0.50
RXFP1 Q9HBX9 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPGD P15428 5/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
GAA P10253 2/20 0.37
NPSR1 Q6W5P4 5/20 0.36
DHFR P00374 1/20 0.36
HSD17B10 Q99714 3/20 0.36
USP2 O75604 3/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
MAPK1 P28482 2/20 0.36
LMNA P02545 2/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864987 0.90 KDM4E (0.51) KDM4EALDH1A1RXFP1TDP1HPGD
SCHEMBL4855957 0.89 KDM4E (0.47) KDM4EALDH1A1RXFP1TDP1HPGD
SCHEMBL4854626 0.89 KDM4E (0.47) KDM4EALDH1A1RXFP1TDP1HPGD
SCHEMBL4855936 0.89 ALDH1A1 (0.48) KDM4EALDH1A1RXFP1HPGDKMT2A
SCHEMBL2951048 0.89 ALDH1A1 (0.48) KDM4EALDH1A1RXFP1HPGDKMT2A
SCHEMBL4854822 0.88 KDM4E (0.47) KDM4EALDH1A1
SCHEMBL14223700 0.88 KDM4E (0.47) KDM4EALDH1A1RXFP1TDP1HPGD
SCHEMBL4857021 0.87 KDM4E (0.48) KDM4EALDH1A1RXFP1HPGDKMT2A
SCHEMBL4861613 0.87 KDM4E (0.48) KDM4EALDH1A1RXFP1HPGDKMT2A
SCHEMBL4858580 0.87 RXFP1 (0.50) KDM4EALDH1A1RXFP1TDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US claimed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US claimed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
WO-2006129181-A2 PREPARATION OF 4-PYRIMIDONE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES ORCHID RESEARCH LABORATORIES LIMITED (IN) 2006-12-07 WO disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP KDM4E 4161/4885ALDH1A1 272/4885RXFP1 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.